**RESEARCH Open Access**

# Local *GHR* roles in regulation of mitochondrial function through mitochondrial biogenesis during myoblast diferentiation



Bowen Hu<sup>1,2,3</sup>, Changbin Zhao<sup>1,2,3</sup>, Xiangchun Pan<sup>3</sup>, Haohui Wei<sup>1,2,3</sup>, Guodong Mo<sup>1,2,3</sup>, Mingjian Xian<sup>1,2,3</sup>, Wen Luo<sup>1,2,3</sup>, Qinghua Nie<sup>1,2,3</sup>, Hongmei Li<sup>1,2,3</sup> and Xiguan Zhang<sup>1,2,3\*</sup>

#### **Abstract**

**Background** Myoblast diferentiation requires metabolic reprogramming driven by increased mitochondrial biogenesis and oxidative phosphorylation. The canonical GH-GHR-IGFs axis in liver exhibits a great complexity in response to somatic growth. However, the underlying mechanism of whether local *GHR* acts as a control valve to regulate mitochondrial function through mitochondrial biogenesis during myoblast diferentiation remains unknown.

**Methods** We manipulated the *GHR* expression in chicken primary myoblast to investigate its roles in mitochondrial biogenesis and function during myoblast diferentiation.

**Results** We reported that *GHR* is induced during myoblast diferentiation. Local *GHR* promoted mitochondrial biogenesis during myoblast diferentiation, as determined by the fuorescence intensity of Mito-Tracker Green staining and MitoTimer reporter system, the expression of mitochondrial biogenesis markers (*PGC1α*, *NRF1*, *TFAM*) and mtDNA encoded gene (*ND1*, *CYTB*, *COX1*, *ATP6*), as well as mtDNA content. Consistently, local *GHR* enhanced mitochondrial function during myoblast diferentiation, as determined by the oxygen consumption rate, mitochondrial membrane potential, ATP level and ROS production. We next revealed that the regulation of mitochondrial biogenesis and function by *GHR* depends on *IGF1*. In terms of the underlying mechanism, we demonstrated that *IGF1* regulates mitochondrial biogenesis via PI3K/AKT/CREB pathway. Additionally, *GHR* knockdown repressed myoblast diferentiation.

**Conclusions** In conclusion, our data corroborate that local *GHR* acts as a control valve to enhance mitochondrial function by promoting mitochondrial biogenesis via IGF1-PI3K/AKT/CREB pathway during myoblast diferentiation.

**Keywords** *GHR*, *IGF1*, Mitochondrial biogenesis, Mitochondrial function, Myoblast diferentiation

\*Correspondence: Xiquan Zhang xqzhang@scau.edu.cn Full list of author information is available at the end of the article



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativecommons.org/licenses/by/4.0/.](http://creativecommons.org/licenses/by/4.0/) The Creative Commons Public Domain Dedication waiver ([http://creativeco](http://creativecommons.org/publicdomain/zero/1.0/) [mmons.org/publicdomain/zero/1.0/](http://creativecommons.org/publicdomain/zero/1.0/)) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

#### **Introduction**

Growth hormone receptor (GHR) belongs to the class I cytokine receptor family, which is an amino acid dimeric receptor contains an extracellular domain (ECD), a single-pass transmembrane domain (IMD) and a cytoplasmic intracellular domain (ICD) [[1,](#page-16-0) [2](#page-16-1)]. Following the binding of GH to GHR, manifold signal cascades are activated, including Janus kinases (JAKs)/signal transducers and activators of transcription (STATs) [\[3](#page-16-2)], mitogenactivated protein kinases (MAPK) [[4\]](#page-16-3), phosphoinositide-3-kinase (PI3K)/Protein kinase B (PKB or AKT) [[5\]](#page-16-4) and phospholipase C (PLC)/Protein kinase C (PKC) [[6\]](#page-16-5). One of the well documented is the GH-GHR-IGFs axis, in which GH combines with GHR to regulate insulin-like growth factor 1 (IGF1), IGF2, IGF-binding protein 3 (IGFBP3) and acid labile subunit (ALS) through JAK2/ STAT5 pathway [\[7](#page-16-6)]. As part of the somatotropic hypothalamic-pituitary system, the canonical GH-GHR-IGFs axis in liver exhibits a great complexity in response to somatic growth, including cell proliferation, diferentiation, division, and survival.

Skeletal muscle is constructed by a cohort of muscle fibers generated from myoblast  $[8]$  $[8]$ . The process of myoblast proliferation and diferentiation into myotube, also termed as myogenesis, is an intricate process requiring a precisely controlled regulation that occurs during embryonic development, as well as muscle regeneration and repair  $[9]$  $[9]$ . Therefore, myoblasts play a pivotal role in skeletal muscle growth and formation. In mammals, GH promotes C2C12 cell proliferation and inhibits its differentiation through an autocrine manner [[10\]](#page-16-9). In poultry, chicken GH (cGH) does not afect its daily gain, feed conversion rate or muscle growth [\[11,](#page-16-10) [12](#page-16-11)]. However, cGH increases *GHR* expression in vitro to promote the proliferation of satellite cells and inhibit their diferentiation [\[13\]](#page-16-12). Knockout of *GHRKO* or *IGF1R* in mouse skeletal muscle elicits impaired muscle development and a decrease in the number and size of muscle fbers, which can be attributed to the reduction of myoblast fusion during muscle development [\[14,](#page-16-13) [15\]](#page-16-14). Our previous research revealed that mutations in *GHR* render a decrease in the number and diameter of muscle fbers in 14-embyro-age and 7-week-age sex-linked dwarf (SLD) chicken [[16\]](#page-16-15), indicating that local *GHR* may afect the growth and development of skeletal muscle in the embryonic stage.

Cellular adenosine triphosphate (ATP) is mainly generated by mitochondria through oxidative phosphorylation (OXPHOS). During the process of cancer cell proliferation, mitochondria must remain repressive to promote cell proliferation. Even in the presence of oxygen, energy still preferentially obtains from the glycolysis, which is termed as "Warburg efect" [\[17](#page-16-16)]. Consequently, raising mitochondrial activity can inhibit myoblast proliferation [[18\]](#page-16-17). On the contrary, myotube is a highly metabolically active cell type, and heavily depends on OXPHOS to provide ATP [[18](#page-16-17)]. Evidence for mitochondrial dysfunction inhibiting myoblast diferentiation has been provided by multiple studies with a series of model systems [[19](#page-16-18)[–24](#page-16-19)]. Thus, myoblast differentiation requires metabolic reprogramming, which leads to an increase in OXPHOS and mitochondrial mass through regulating mitochondrial biogenesis [[25–](#page-16-20)[30](#page-17-0)]. Mitochondrial biogenesis is a selfrenewal process that requires coordination between mitochondrial DNA (mtDNA) and nuclear DNA (nDNA), including mtDNA transcription and translation, translation of nDNA encoded transcripts, protein import and assembly of the OXPHOS complexes [\[31](#page-17-1)]. Our previous review has summarized the versatile relationship between GH-GHR-IGF1 axis, mitochondrial biogenesis and mitochondrial function, and postulated that the efects of GH-GHR-IGFs axis on mitochondrial biogenesis and function might be mostly mediated by IGF1 [[32\]](#page-17-2). However, the roles of local *GHR* in the regulation of mitochondrial biogenesis and function during myoblast diferentiation is not clear.

Given this, we manipulated the *GHR* expression in chicken muscle stem cell to investigate its roles in mitochondrial biogenesis and function during myoblast differentiation. We found that local *GHR* acts as a control valve to enhance mitochondrial function by promoting mitochondrial biogenesis via IGF1-PI3K/AKT/CREB during myoblast diferentiation. Understanding the precise roles of local *GHR* in myoblast diferentiation may provide attractive tools for the development of efective molecular therapies to treat muscle-related diseases, including sarcopenia and muscle atrophy. In the future, this may also pave the new avenues for the development of new strategies targeting mitochondria to promote muscle development for the cultivated meat industry and even improve some muscle developmental defects.

### **Materials and methods**

#### **Cell culture**

Chicken primary myoblast was isolated from the chicken leg muscle on embryonic 11 day as previous described [[33\]](#page-17-3). Chicken primary myoblast (CPM) was cultured with growth medium (GM) consisting of RPMI-1640 medium (Gibco, USA), 15% fetal bovine serum (FBS) (Gibco, USA), and 0.2% penicillin/streptomycin. After myoblasts achieving 90% cell confuence, the GM was then removed and replaced with diferentiation medium (DM) consisting of RPMI-1640 medium without FBS, 2% horse serum and 0.2% penicillin/streptomycin. All cells were cultured at 37 °C in a 5%  $CO<sub>2</sub>$  humidified atmosphere.

#### **RNA extraction and real‑time quantitative PCR**

Total RNA was extracted from cells with RNAiso reagent (Takara, Japan) according to the manufacturer's protocol. The RNA integrity and concentration were determined using 1.5% agarose gel electrophoresis and a Nanodrop 2000c spectrophotometer (Thermo, USA), respectively. cDNA was synthesized using PrimeScript RT reagent Kit (Takara, Japan) for Real-Time quantitative PCR (RT $qPCR$ ). The MonAmp<sup>™</sup> ChemoHS qPCR Mix (Monad, China) was utilized for RT-qPCR in a Bio-Rad CFX96 Real-Time Detection instrument (Bio-Rad, USA) according to the manufacturer's protocol. Relative gene expression was measured by RT-qPCR and nuclear gene *β-actin* was utilized as a control. The primers utilized in RTqPCR were shown in Table S[1](#page-15-0) and synthesized by Sangon Biotech (Shanghai, China).

#### **DNA extraction and analysis of mtDNA copy number**

Total nuclear DNA and mtDNA were extracted from cells with a DNA tissue kit (Omega, USA) according to the manufacturer's protocol. The DNA integrity and concentration were determined using 1.5% agarose gel electrophoresis and a Nanodrop 2000c spectrophotometer (Thermo, USA), respectively. The MonAmp $\textsuperscript{TM}$  ChemoHS qPCR Mix (Monad, China) was utilized for RT-qPCR in a Bio-Rad CFX96 Real-Time Detection instrument (Bio-Rad, USA) according to the manufacturer's protocol. Relative mtDNA copy number was measured by RT-qPCR performed twice for each reaction using specifc primers for mtDNA *ND1* gene and alternate primers for mtDNA *tRNA-Leu* gene (NC\_053523.1), a nuclear single-copy gene *β2M* was utilized as a control. The primers utilized in RT-qPCR were shown in Table S[1](#page-15-0) and synthesized by Sangon Biotech (Shanghai, China).

#### **RNA interference**

The siRNAs used for the knockdown of *GHR*, *IGF1* and *CREB* were synthesized by Guangzhou RiboBio (Guangzhou, China). In our preliminary experiments, we designed three siRNA for each gene and selected the siRNA with the highest interference efficiency. si-*GHR*, si-*IGF1*, si-*CREB* and si-NC were transfected in cells to a fnal concentration of 150 nM, and cells were analyzed at 48 h after transfection. The sequence of siRNA was shown in Table  $S2$ . The inhibition efficiencies were detected by the fuorescence intensity of Cy3 siRNA and RT-qPCR.

#### **Plasmids construct**

Overexpression vectors: *GHR* coding sequence (NCBI Reference Sequence: NM\_001001293.2), *IGF1* coding sequence (NCBI Reference Sequence: NM\_001004384.3) and *CREB1* coding sequence (NCBI Reference Sequence: NM NM 204450.3) were amplified from chicken cDNA and cloned into the pcDNA3.1 vector (Invitrogen, USA). PGC1 $α$  promoter reporter plasmids were amplified from chicken cDNA cloned into the pGL3-basic luciferase reporter vector (Promega, USA). p*MitoTimer* was a gift from Zhen Yan (Addgene plasmid, 52,659), and empty vector p*CI-neo* (Promega, USA) was utilized as internal control. All plasmid constructs were confrmed by DNA sequencing.

#### **Transfection**

Cells were plated in culture plates and incubated overnight prior to the transfection experiment. Transfection was performed with the Lipofectamine 3000 reagent (Invitrogen, USA) following the manufacturer's protocol and nucleic acids were diluted in OPTI-MEM Medium (Gibco, USA). Transfection was performed when myoblasts achieved 90% cell confuence, GM was then removed and replaced with DM after transfection was complete. All cells were analyzed at 48 h after transfection.

#### **Mito‑Tracker Green staining and Hoechst 33,342 staining**

Mito-Tracker Green (MTG) staining and Hoechst 33,342 staining was used to label the mitochondria and nuclei in cells, respectively. DMSO (Beyotime, Shanghai, China) was utilized as internal control. Cells were washed twice with PBS and incubated with Mito-Tracker Green (Beyotime, Shanghai, China) for 30 min at 48 h after transfection. Cells were then suspended in PBS and 10 μL of Hoechst 33,342 dye was added (Beyotime, Shanghai, China). After being washed in PBS twice, a fuorescence microscope (TE2000-U; Nikon, Japan) was used to capture fve randomly selected felds and analyzed with NIS-Element's software.

#### **Western blot analysis**

Cellular protein was lysed by radio immune precipitation assay (RIPA) bufer (Beyotime, China) with phenylmethane sulfonyl fuoride (PMSF) protease inhibitor (Beyotime, China) and the homogenate was centrifuged at 12,000 $\times$ g for 5 min at 4 °C. The supernatant was collected and the protein concentration was determined immediately using a BCA protein quantifcation kit (Beyotime, China). The proteins were separated in 10% SDS-PAGE and transferred onto PVDF membrane, and then probed with antibodies following standard procedures. The antibodies and their dilutions utilized for western blots were as follow: anti-GHR (bs-0654R; Bioss, China; 1:500), anti-PGC1α (bs-1832R; Bioss, China; 1:500), anti-NRF1 (12,482–1-AP; Proteintech, USA; 1:500), anti-TOMM20 (AF1717; Beyotime, China; 1:500), anti-JAK2

(bs-0908R; Bioss, China; 1:1000), anti-p-JAK2 (bsm-52171R; Bioss, China; 1:1000), anti-AKT1 (bs-0115 M; Bioss, China; 1:500), anti-p-AKT1 (66,444–1-Ig; Proteintech, China; 1:500), anti-CREB1 (bs-0035R; Bioss, China; 1:500), anti-p-CREB1 (bs-0036R; Bioss, China; 1:500), anti-β-actin (bs-0061R; Bioss, China; 1:1000), goat antirabbit IgG-HRP (bs-0295G; Bioss, China; 1:5000), goat anti-mouse IgG-HRP (bs-0296G; Bioss, China; 1:5000).

#### **Dual‑luciferase reporter assay**

For promoter validation, the cells were transfected with a series of the promoter reporter plasmids described above and the TK-Renilla reporter (Promega, USA) was cotransfected as internal control. For interaction assays, the promoter reporter plasmids were co-transfected with the *CREB* overexpression vector in CPM and the TK-Renilla reporter (Promega, USA) was co-transfected as internal control. At 48 h after transfection, the luciferase activities of the cells were measured using the Dual-Glo® Luciferase Assay System (Promega, USA) and Fluorescence/ Multi-Detection Microplate Reader (BioTek, USA). The levels of frefy luciferase activity were normalized to Renilla luciferase activity.

#### **Detection of reactive oxygen species**

Reactive oxygen species (ROS) production was measured using an ROS assay kit (Beyotime, China) according to the manufacturer's protocol. Dichlorofuorescein (DCF) fuorescence was determined using a Fluorescence/ Multi-Detection Microplate Reader (BioTek, USA).

#### **Detection of ATP content**

ATP levels were measured using an ATP assay kit (Beyotime, China) according to the manufacturer's protocol. A Fluorescence/Multi-Detection Microplate Reader (BioTek, USA) was used to determine luminescence level.

#### **Detection of mitochondrial membrane potential**

Mitochondrial membrane potential (ΔΨm) was measured using a JC-1 kit (Beyotime, China) according to the manufacturer's protocol. The fluorescence was determined using a flow cytometer (BD Biosciences, USA) after the cells were incubated with JC-1 for 20 min at 37 °C; 10 µM rotenone was used as a standard inhibitor of ΔΨm.

#### **Oxygen consumption**

Oxygen consumption rate (OCR) in CPM was measured utilizing a Seahorse XF Cell Mito Stress Test Kit (103,015, Agilent Technologies, USA) and Seahorse Extracellular Flux Analyzer (Agilent) according to the manufacturer's protocol. Cells were plated on a miniplate 24 h prior to the Seahorse assay. The OCR was monitored upon following sequential injections of oligomycin  $(1 \mu M)$ , FCCP  $(1 \mu M)$ , and a rotenone/antimycin A mixture  $(1.5 \mu M)$ .

#### **Cell counting kit‑8 assays**

Cells were seeded in 96-well plates and cultured in growth medium. After transfection, the proliferation of the cell culture was monitored at 12, 24, 36 and 48 h using a Cell Counting Kit-8 (CCK-8) kit (Beyotime, China) according to the manufacturer's protocol. The absorbance at 450 nm was determined using a Fluorescence/Multi-Detection Microplate Reader (BioTek, USA). The data were acquired by averaging the results from six independent repeats.

#### **5‑ethynyl‑20‑deoxyuridine assays**

Cells were seeded in 24-well plates and cultured to 50% density for transfection. Cells were fxed and stained with a 5-ethynyl-20-deoxyuridine (EdU) imaging kit (RiboBio, China) according to the manufacturer's protocol. A fuorescence microscope (DMi8; Leica, German) was used to capture three randomly selected felds to visualize the number of EdU stained cells.

#### **Immunofuorescence**

The immunofluorescence was performed using anti-MyHC (B103; DSHB, USA; 1:50). After transfection for 48 h, cells were fxed in 4% formaldehyde for 20 min then washed three times with PBS for 5 min. Subsequently, the cells were permeabilized by adding 0.1% Triton X-100 for 15 min and blocked with goat serum for 30 min. After overnight incubation with anti-MyHC at 4 °C, the Dylight 594-conjugated AfniPure Goat Anti-Mouse IgG (H+L) (BS10027; Bioworld, USA; 1:100) was added and the cells were incubated in dark for 1 h. The cell nuclei were stained with DAPI (Beyotime, China). Results were visualized on a fuorescence microscope (DMi8; Leica, German) and measured by using ImageJ software (National Institutes of Health). Myotube area was calculated as the percentage of the total image area covered by myotubes.

#### **Statistical analysis**

All the experiments were performed at least three times. The graphical representation was performed in Graph-Pad Prism v9.0 software (GraphPad Software, USA). The error bar was presented as means±standard error of the mean (S.E.M.). The statistical analyze was performed using two-sided Student's *t*-test, and we considered  $p$ <0.05 to be statistically significant,  $p$  <0.05, \*\* $p$  <0.01.

#### **Results**

#### **High** *GHR* **expression during myoblast diferentiation**

To understand whether local *GHR* afects the growth and development of skeletal muscle during embryonic stage, we frst investigated the *GHR* expression profle in the myoblast proliferation and diferentiation phases. *GHR* expression increased gradually during myoblast differentiation, up to tenfold in comparison to proliferating cells (Fig. [S1](#page-15-1)a). In vivo, *GHR* is highly expressed during embryo age 10 (E10)-E14, but is relatively low after E18 in leg muscle [[34](#page-17-4)]. These results suggest that *GHR* mainly play its roles during myoblast diferentiation.

Myoblasts demand two stages to form the multinucleated myotubes in vitro [[14](#page-16-13), [15](#page-16-14)]. First, two myoblasts fuse to form a nascent myotube at 24 h after induction of differentiation. During the next phase (24–48 h), additional myoblasts fuse to this nascent myotube to produce a fully differentiated myotube. Therefore, we overexpressed or interfered with related genes during the myoblast differentiation phase (Fig. S[1b](#page-15-1)). To confrm that plasmid or siRNA was successfully transfected into cells during myoblast diferentiation, we utilized pcDNA3.1-EGFP or  $siNC-Cy3$  to determine the transfection efficiency (Fig. S[1c](#page-15-1), d).

#### **Local** *GHR* **promotes mitochondrial biogenesis**

We asked whether local *GHR* regulates mitochondrial biogenesis during myoblast diferentiation using *GHR* knockdown and overexpression. Knockdown or overexpression efficiency was measured by RT-qPCR and western blot (Fig. [1](#page-5-0)a, j, k; [S2](#page-15-1)a, j, k). Regarding GH-GHR-IGFs axis, *GHR* knockdown decreased the expression of *IGF1*, but did not alter the expression of *GH* and *IGF2* (Fig. [1b](#page-5-0)), indicating that *GHR* might exert its downstream roles through auto/paracrine *IGF1*. On the contrary, *GHR* overexpression promoted the expression of *GH* and *IGF1* (Fig. S[2b](#page-15-1)), indicating a positive feedback regulation mechanism.

Next, we investigated the efects of *GHR* on mitochondrial biogenesis by frst measuring mitochondrial mass using MTG staining. *GHR* knockdown reduced mitochondrial mass (Fig. [1c](#page-5-0), d), while overexpression of *GHR* was accompanied by an increase in mitochondrial mass (Fig. S[2c](#page-15-1), d). To further verify the efects of *GHR* on mitochondrial biogenesis during myoblast diferentiation, we utilized a *MitoTimer* reporter gene. p*MitoTimer* expresses a mitochondrial targeted DsRed protein that changes from green fuorescence to red in mitochondria within 48 h; therefore, it can help to distinguish newly synthesized mitochondria from mature mitochondria [[35\]](#page-17-5). *GHR* knockdown increased the ratio of red signal to green signal (Fig. [1e](#page-5-0), f), while overexpression of *GHR* decreased this ratio (Fig. S[2e](#page-15-1), f), indicating that *GHR* promotes the synthesis of new mitochondria. We then examined the expression of *PGC1α*, *NRF1* and *TFAM*, which are markers of mitochondrial biogenesis, after transfection. *GHR* knockdown decreased the expression of *PGC1α*, *NRF1* and *TFAM* (Fig. [1](#page-5-0)g), while *GHR* overexpression had the opposite effects (Fig.  $S2g$  $S2g$ ). We also investigated the effects of *GHR* on mtDNA transcription and replication. *GHR* knockdown repressed the expression of mtDNA encoded gene (represented by *ND1*、*CYTB*、*COX1*、*ATP6*), and mtDNA copy number (represented by *ND1* and *tRNA-Leu*) (Fig. [1](#page-5-0)h, i). Opposite results were found after we overexpressed *GHR* (Fig. [S2](#page-15-1)h, i). Finally, we examined the protein levels of mitochondrial biogenesis markers. *GHR* knockdown decreased the protein level of PGC1α, NRF1 and TOMM20 (Fig. [1j](#page-5-0), l), while overexpression of *GHR* increased the protein level of these markers (Fig. S[2j](#page-15-1), l). Taken together, these results suggest that local *GHR* promotes mitochondrial biogenesis during myoblast diferentiation.

#### *IGF1* **promotes mitochondrial biogenesis**

We then asked whether auto/paracrine produced IGF1 afects mitochondrial biogenesis during myoblast diferentiation using *IGF1* knockdown and overexpression. Knockdown or overexpression efficiency was measured by RT-qPCR (Fig. [2a](#page-6-0); S[3a](#page-15-1)). Regarding GH-GHR-IGFs axis, *IGF1* knockdown decreased the expression of *GH*, but did not alter the expression of *GHR* and *IGF2* (Fig. [2](#page-6-0)b), indicating a positive feedback regulation mechanism involved in *IGF1* roles. Notably, *IGF1* overexpression repressed the expression of *GH, GHR* and *IGF2* (Fig. S[3b](#page-15-1)), indicating a negative feedback regulation mechanism that is opposite to the results of *IGF1* knockdown.

Like the results acquired with *GHR* above, *IGF1* knockdown reduced mitochondrial mass (Fig. [2](#page-6-0)c, d), while overexpression of *IGF1* was accompanied by an increase in mitochondrial mass (Fig.  $S3c$  $S3c$ , d). As for MitoTimer reporter system, *IGF1* knockdown increased the ratio of red signal to green signal (Fig. [1](#page-5-0)e, f), while overexpression of *IGF1* decreased this ratio (Fig. S[2e](#page-15-1), f), indicating that *IGF1* promotes the synthesis of new mitochondria. Accordingly, *IGF1* knockdown decreased the expression of *PGC1α*, *NRF1* and *TFAM* (Fig. [2](#page-6-0)g), while *IGF1* overexpression had the opposite efects (Fig. S[2g](#page-15-1)). In parallel, *IGF1* knockdown repressed the expression of mtDNA encoded gene (represented by *ND1*、*CYTB*、*COX1*、*ATP6*), and mtDNA copy number (represented by *ND1* and *tRNA-Leu*) (Fig. [2h](#page-6-0), i). Opposite results were found after we overexpressed *IGF1* (Fig. [S3](#page-15-1)h, i). Additionally, we examined the protein level of mitochondrial biogenesis markers. *IGF1*



<span id="page-5-0"></span>si-*GHR* and si-NC. **b** The expression of genes involved in the GH-GHR-IGFs signaling pathway was measured by RT-qPCR at 48 h after transfection with si-*GHR* and si-NC. **c** and **d** MTG staining of CPM was measured at 48 h after transfection with si-*GHR* and si-NC. White arrow labeled elongated myoblasts. Scaler bar, 25 μm. **e** and **f** Confocal images were observed at 48 h after co-transfection with p*MitoTimer*+si-*GHR* and p*MitoTimer*+si-NC. Scaler bar, 10 μm. Green represents newly synthesized mitochondria, red represents mature mitochondria. Images were analyzed by Leica LAS X life science software. **g** The expression of genes involved in PGC1α-NRF1-TFAM signaling pathway was measured by RT-qPCR at 48 h after transfection with si-*GHR* and si-NC. **h** The expression of mtDNA encoded genes was measured by RT-qPCR at 48 h after transfection with si-*GHR* and si-NC. **i** The relative mtDNA content was measured by RT-qPCR at 48 h after transfection with si-*GHR* and si-NC. **j-l** Western blots with anti-GHR, anti-PGC1α, anti-NRF1 and anti-β-actin at 48 h after transfection with si-*GHR* and si-NC. Data are shown as mean±SEM, \**p*<0.05, \*\**p*<0.01

knockdown decreased the protein level of PGC1α, NRF1 and TOMM20 (Fig. [2j](#page-6-0), k), while overexpression of *IGF1* increased the protein level of these markers (Fig. S[3](#page-15-1)j, k). Altogether, these results suggest that *IGF1* promotes mitochondrial biogenesis during myoblast diferentiation.



<span id="page-6-0"></span>si-*IGF1* and si-NC. **b** The expression of genes involved in the GH-GHR-IGFs signaling pathway was measured by RT-qPCR at 48 h after transfection with si-*IGF1* and si-NC. **c** and **d** MTG staining of CPM was measured at 48 h after transfection with si-*IGF1* and si-NC. White arrow labeled elongated myoblasts. Scaler bar, 25 μm. **e** and **f** Confocal images were observed at 48 h after co-transfection with p*MitoTimer*+si-*IGF1* and p*MitoTimer*+si-NC. Scaler bar, 10 μm. Green represents newly synthesized mitochondria, red represents mature mitochondria. Images were analyzed by Leica LAS X life science software. **g** The expression of genes involved in PGC1α-NRF1-TFAM signaling pathway was measured by RT-qPCR at 48 h after transfection with si-*IGF1* and si-NC. **h** The expression of mtDNA encoded genes was measured by RT-qPCR at 48 h after transfection with si-*IGF1* and si-NC. **i** The relative mtDNA content was measured by RT-qPCR at 48 h after transfection with si-*IGF1* and si-NC. **j** and **k** Western blots with anti-PGC1α, anti-NRF1 and anti-β-actin at 48 h after transfection with si-*IGF1* and si-NC. Data are shown as mean±SEM, \**p*<0.05, \*\**p*<0.01

#### **Regulation of mitochondrial biogenesis by** *GHR* **depends on** *IGF1*

The tight connection between *GHR* and *IGF1* along with the synchronous results prompted us asked whether *IGF1* could mitigate the impairments of *GHR* knockdown on mitochondrial biogenesis. Therefore, we knocked down *GHR* in presence and absence of *IGF1* overexpression during myoblast differentiation. The expression of genes involved in GH-GHR-IGFs axis were coincided with the results as above (Fig. [3](#page-7-0)a). Using MTG staining, MitoTimer reporter system, RT-qPCR and western blots, we found that overexpression of *IGF1* completely restored or reversed the impairments of *GHR* knockdown on mitochondrial biogenesis (Fig. [3b](#page-7-0)-j), indicating that the regulation of mitochondrial biogenesis by *GHR* depends on *IGF1*.

#### **Local** *GHR* **regulates mitochondrial biogenesis via IGF1‑PI3K/AKT/CREB pathway**

Next, we aimed to identify the underlying mechanism by which local *GHR* promotes mitochondrial biogenesis during myoblast diferentiation. GH combines with GHR to regulate IGF1 production via the JAK2/STAT5 pathway through endocrine and paracrine/autocrine mechanisms [[36,](#page-17-6) [37\]](#page-17-7). IGF1 binds to its receptor to activate the PI3K/AKT signaling pathway in murine fibroblasts [\[38](#page-17-8)]. AKT regulates the phosphorylation of the transcription factor CREB to promote human 293 T cells survival [\[39](#page-17-9)]. Phosphorylated CREB further activates downstream *PGC1α* transcription through cAMP response element in human hepatoma HepG2 cells [[40\]](#page-17-10). By using the String database, there is indeed a potential protein–protein interaction (PPI) network among GHR, IGF1, AKT, CREB and PGC1 $α$  in diverse species (Fig. [4a](#page-9-0)-d). Based on these foregoing results, we wondered if local *GHR* might regulate mitochondrial biogenesis via IGF1-PI3K/ AKT/CREB pathway during myoblast diferentiation.

To test this hypothesis, we frst determined the expression levels of related proteins involved in this pathway by western blots. *GHR* knockdown decreased the protein level of  $p$ -JAK2  $\cdot$   $p$ -AKT and  $p$ -CREB (Fig. [4e](#page-9-0), f), while *GHR* overexpression increased the protein levels (Fig. S[4a](#page-15-1), b). Likewise, *IGF1* knockdown decreased the protein level of p-AKT and p-CREB (Fig. [4g](#page-9-0), h), while *IGF1* overexpression had an opposite result (Fig. S[4c](#page-15-1), d). Moreover, overexpression of *IGF1* also reversed the efects of reduced protein level in *GHR* knockdown cells (Fig. [4i](#page-9-0), j).

To further evaluate if the efect of *IGF1* on mitochondrial biogenesis was transmitted through PI3K/AKT pathway, we treated the cells with LY294002 (PI3K inhibitor) or GSK690693 (AKT inhibitor) after *IGF1* overexpression during myoblast diferentiation. We observed that these PI3K/AKT pathway inhibitors signifcantly decreased CREB protein phosphorylation level (Fig. [4](#page-9-0)m, n). Among the same line, *PGC1α* mRNA and protein expression were both decreased after blunting the PI3K/ AKT pathway (Fig. [4k](#page-9-0)-n).

We next manipulated *CREB* expression to examine whether *PGC1α* expression was regulated by this transcription factor during myoblast differentiation. The results revealed that, as expected, signifcant increase of *PGC1α* expression and its protein level after *CREB* overexpression (Fig. [4o](#page-9-0)-q). Further investigation using dual-luciferase assays transfected with reporter vectors containing diferent lengths of 2000 bp upstream region of *PGC1α* (Fig. [4r](#page-9-0)). Dual-luciferase assays revealed that signifcantly increased luciferase activity in diferent pGL3-PGC1α reporter vectors in *CREB* overexpressed cells, indicating that CREB directly promoted the transcription of *PGC1α* by acting on the proximal promoter region (Fig. [4](#page-9-0)s). Inversely, *CREB* knockdown had the opposite efects (Figure [S4](#page-15-1)e-h). Taken together, we demonstrate that local *GHR* regulates mitochondrial biogenesis via IGF1-PI3K/AKT/CREB pathway during myoblast diferentiation.

#### **Local** *GHR* **enhances mitochondrial function through** *IGF1*

Mitochondrial biogenesis plays an essential role in maintaining normal mitochondrial OXPHOS, raising the question of whether inhibited mitochondrial biogenesis by *GHR* knockdown could ultimately result in impaired mitochondrial function during myoblast diferentiation. To explore this, we frst performed mitochondrial membrane potential, luminescence-based ATP level and ROS production assay to evaluate mitochondrial function. *GHR* knockdown impaired mitochondrial function, as

<span id="page-7-0"></span>**Fig. 3** Regulation of mitochondrial biogenesis by *GHR* depends on *IGF1*. **a** The expression of genes involved in the GH-GHR-IGFs signaling pathway was measured by RT-qPCR at 48 h after co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. **b** and **c** MTG staining of CPM was measured at 48 h after transfection with co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. White arrow labeled elongated myoblasts. Scaler bar, 25 μm. **d** and **e** Confocal images were observed at 48 h after co-transfection with p*MitoTimer*+si-*GHR*+pcDNA3.1-*IGF1*,+si-*GHR*+pcDNA3.1 and+si-NC+pcDNA3.1. Scaler bar, 10 μm. Green represents newly synthesized mitochondria, red represents mature mitochondria. Images were analyzed by Leica LAS X life science software. **f** The expression of genes involved in PGC1α-NRF1-TFAM signaling pathway was measured by RT-qPCR at 48 h after co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. **g** The expression of mtDNA encoded genes was measured by RT-qPCR at 48 h after co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. **h** The relative mtDNA content was measured by RT-qPCR at 48 h after co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. **i** and **j** Western blots with anti-PGC1α, anti-NRF1 and anti-β-actin at 48 h after co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. Data are shown as mean±SEM, \**p*<0.05, \*\**p*<0.01

<sup>(</sup>See fgure on next page.)



**Fig. 3** (See legend on previous page.)

indicated by reduced ΔΨm and ATP level as well as ROS production (Fig. [5](#page-11-0)a, c, d). However, *GHR* overexpression enhanced mitochondrial function (Fig. S[5a](#page-15-1), c, d). Same consequences were observed after *IGF1* knockdown or overexpression (Fig. [5b](#page-11-0), e, f; [S5](#page-15-1)b, e, f). Furthermore, *IGF1* overexpression ameliorated the efects of *GHR* knockdown on mitochondrial function (Fig. [5](#page-11-0)l-m).

On the other hand, we measured mitochondrial OXPHOS utilizing Seahorse Extracellular Flux Analyzer after *GHR* and *IGF1* overexpression to recapitulate the results above. We found that *GHR* and *IGF1* overexpression enhanced oxygen consumption rate (OCR), with the control groups showing lower basal and maximal respiration (Fig. [5](#page-11-0)g-i). *GHR* and *IGF1* overexpression also had higher ATP production as measured by inhibition of ATP synthase with oligomycin, which led to smaller decrease in the basal respiration of control groups (Fig. [5j](#page-11-0)). Meanwhile, *GHR* and *IGF1* overexpression repressed proton leakage as measured by inhibiting complex I and III by rotenone and antimycin-A, which may explain the higher ROS production with enhanced mitochondrial function under normal physiology condition (Fig. [5k](#page-11-0)). Consistently, *IGF1* overexpression partially alleviated the efects of *GHR* knockdown on mitochondrial respiration (Fig. [5](#page-11-0)o-s). Altogether, these results suggest that local *GHR* enhances mitochondrial function through *IGF1* during myoblast diferentiation.

#### *GHR* **knockdown represses myoblast diferentiation**

Next, we sought to understand the efects of local *GHR* on myoblast proliferation and diferentiation. Using CCK-8 and EdU assays, we found that *GHR* knockdown or overexpression did not alter myoblast proliferation cultured in GM (Fig.  $6a-c$  $6a-c$ ; S $6a-c$ ). This is further supported by the fact that *GHR* had no infuence on the number of cells in G0, S and G1 phase and the expression of cell proliferation marker genes (Fig. [6d](#page-12-0), e; S[6d](#page-15-1), e), indicating that *GHR* does not afect myoblast proliferation.

Previous studies have found that GH signaling afects myoblast development by stimulating accumulation of additional myonuclei into nascent myotubes (myoblast fusion) induced by NFATc2 in a cell-autonomous manner [[14,](#page-16-13) [15](#page-16-14)]. Similarly, our *GHR* knockdown repressed the formation of myotubes, decreased the proportion of myotubes with more than ten nuclei, and inhibited the expression of *NFATc2* in CPM (Fig. [6](#page-12-0)f-i). Of note, we unexpectedly found that *GHR* overexpression also repressed myoblast differentiation (Fig. S[6f](#page-15-1)-i). These results suggest that *GHR* knockdown represses myoblast diferentiation.

#### **Discussion**

At present, canonical GH-GHR-IGF1 axis has been advanced for more than a century, and mostly focuses on the treatment of growth-related disorders [\[7](#page-16-6)]. However, the relationship between local GH-GHR-IGF1 axis and mitochondria during the muscle development is rarely reported. Our previous research revealed that mutations in *GHR* elicit a decrease in the number and diameter of muscle fbers in E14 and 7w SLD chicken [[16\]](#page-16-15), indicating that *GHR* may afect the growth and development of skeletal muscle in the embryonic stage. Myoblasts play a central role in the formation and growth of skeletal muscle. Accordingly, we sought to unveil the molecular mechanism of local *GHR* regulating mitochondrial biogenesis during myoblast diferentiation, and obtained evidence that local *GHR* regulates muscle development in the embryonic stage from the perspective of mitochondria (Fig. [7\)](#page-13-0). It may provide a theoretical basis for the development of inhibitor or activator molecules targeting mitochondria to promote muscle development.

It is well known that myogenesis is a sophisticated process. In mammals, myoblasts frst diferentiate to primary

(See fgure on next page.)

<span id="page-9-0"></span>**Fig. 4** Local *GHR* regulates mitochondrial biogenesis via IGF1-PI3K/AKT/CREB pathway. **a** The PPI network of human GHR, IGF1, AKT, CREB and PGC1α. **b** The PPI network of mouse GHR, IGF1, AKT, CREB and PGC1α. **c** The PPI network of pig GHR, IGF1, AKT, CREB and PGC1α. **d** The PPI network of chicken GHR, IGF1, AKT, CREB and PGC1α. Protein–protein interaction was performed by the String database and visualized by Cytoscape (version 3.4.0). **e** and **f** Western blots with anti-JAK2, anti-p-JAK2, anti-AKT1, anti-p-AKT1, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after transfection with si-*GHR* and si-NC. **g** and **h** Western blots with anti-AKT1, anti-p-AKT1, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after transfection with si-*IGF1* and si-NC. **i** and **j** Western blots with anti-AKT1, anti-p-AKT1, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after co-transfection with si-*GHR*+pcDNA3.1-*IGF1*, si-*GHR*+pcDNA3.1 and si-NC+pcDNA3.1. **k** LY294002 (PI3K inhibitor) was added at 24 h before measuring the expression of *PGC1α* by RT-qPCR at 48 h after transfection of pcDNA3.1-*IGF1* and pcDNA3.1. **l** GSK690693 (AKT inhibitor) was added at 24 h before measuring the expression of *PGC1α* by RT-qPCR at 48 h after transfection of pcDNA3.1-*IGF1* and pcDNA3.1. **m** and **n** LY294002 or GSK690693 was added at 24 h before measuring the protein levels with anti-PGC1α, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after transfection of pcDNA3.1-*IGF1* and pcDNA3.1. **o** The expression of *CREB* and *PGC1α* was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*CREB* and pcDNA3.1. **p** and **q** Western blots with anti-PGC1α, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after transfection with pcDNA3.1-*CREB* and pcDNA3.1. **r** Dual-Luciferase report assays transfected with reporter vectors containing diferent length of 5′ upstream region of *PGC1α*. **s** Dual-Luciferase report assays of *CREB* overexpression co-transfected with reporter vectors containing diferent length of 5′ upstream region of *PGC1α.* Data are shown as mean±SEM, \**p*<0.05, \*\**p*<0.01



**Fig. 4** (See legend on previous page.)



<span id="page-11-0"></span>



<span id="page-12-0"></span>proliferation assays were performed after transfection with si-*GHR* and si-NC. **d** Cell cycle analysis were performed after transfection with si-*GHR* and si-NC. **e** The expression of cell proliferation marker genes was measured by RT-qPCR at 48 h after transfection with si-*GHR* and si-NC. **f–h** MyHC staining, myotube area and myoblast fusion index were measured at 48 h after transfection with si-*GHR* and si-NC. **i** The expression of myoblast differentiation marker genes was measured by RT-qPCR at 48 h after transfection with si-GHR and si-NC. Data are shown as mean  $\pm$  SEM, \*p < 0.05, \*\**p*<0.01

fbers during embryonic stage (E10.5-E12.5); then, myoblasts and single myoblasts fuse to the existing primary fbers to generate secondary myofbers during fetal stage (E14.5-P0); at last, satellite cell proliferation and fusion with existing myofbers result in myofber growth by rapid increase in myonuclear number during neonatal stage (P0-P21). Consistently, chicken skeletal muscle mainly remains in the period of proliferation and diferentiation before E16, and the fusion of muscle fbers is basically completed after E18. *GHR* is highly expressed during E10-E14, but is relatively low after E18 in leg muscle [[34\]](#page-17-4). In present study, *GHR* expression was relatively high in the diferentiation phase and gradually upregulated during myoblast differentiation. These results suggest that *GHR* mainly plays its roles during myoblast diferentiation. Knockout of *GHR* or addition of GH does not afect the proliferation of myoblasts after 8 h [\[14](#page-16-13),

[15\]](#page-16-14). Here, *GHR* knockdown or overexpression had no impact on myoblast proliferation, further indicating that *GHR* does not account for the process of myoblast proliferation. On the other hand, mitochondrial OXPHOS remains continuously inhibited during myoblast proliferation, but is highly fred during myoblast diferentiation. Based on the above research results, we thereby explored the molecular mechanism of *GHR* regulating mitochondrial function during myoblast diferentiation phase.

*IGF1* sequence is highly conserved among species, whereas *IGF2* is diferent [[41\]](#page-17-11). Like the *GHR* expression profle, *IGF1* is highly induced during E15-E18 in chicken leg muscles, but is relatively low after E18; while *IGF2* is relatively high expression after E18 [\[42](#page-17-12)]. *IGF1* was signifcantly up-regulated after *GHR* overexpression and down-regulated after *GHR* knockdown during myoblast diferentiation, while *IGF2* expression did not



<span id="page-13-0"></span>**Fig. 7** Schematic diagram for the mechanistic model of the *GHR* roles in regulation of mitochondrial function during myoblast diferentiation. Local *GHR* enhances mitochondrial function by promoting mitochondrial biogenesis via *IGF1*-PI3K/AKT/CREB pathway during myoblast diferentiation. This graphical abstract was created with Biorender.com

change. These results indicate that *GHR* mainly played its regulatory roles through endogenous *IGF1* rather than *IGF2* in the embryonic stage. It is generally believed that IGFs are mainly induced by *GHR* in the liver to control the growth and development of animals. However, due to the embryo still lacking a mature circulatory system, IGFs must play their regulatory role through paracrine or autocrine mechanisms in the early embryonic development (before E15-E16) [\[43\]](#page-17-13). IGF1 produced by the liver is not necessary for body growth after birth, GH mainly promotes body growth after birth through autocrine IGF1 in non-liver tissues [\[44](#page-17-14)]. Although *GHR* is scarcely expressed in myoblasts, local *GHR* is likely to act as a control valve during myogenesis. Compliance with the results from Segard et al. (2003), *GHR* overexpression increased the expression of *GH* and *IGF1*, suggesting that GH and IGF1 regulate embryonic myoblast development through an auto/paracrine manner. Besides, *IGF1* knockdown had no efect on *IGF2* expression, while *IGF1* overexpression down-regulated *IGF2* expression, implying that there may be a competing relationship between *IGF1* and *IGF2*.

Mitochondrial biogenesis supports the normal number, structure, and function of mitochondria, which is mainly regulated by nuclear genes through the PGC1α-NRF1- TFAM signaling pathway  $[45-49]$  $[45-49]$  $[45-49]$ . PGC1 $\alpha$  is a member of the PGC1 family, which also includes PGC1β and PRC. PGC1 $α$  acts as a mediator of mitochondrial biogenesis under diferent physiological conditions, whereas the role of PGC1β is limited to the maintenance of basal mitochondrial function. By contrast, PRC function appears to be restricted to the regulation of gene expression in proliferating cells  $[48]$  $[48]$ . These co-activators coordinate with nuclear respiration factors NRF1 and NRF2 to regulate the *TFAM* expression thereby afecting mtDNA replication and transcription [[50\]](#page-17-18). Notably, *TFAM* expression

does not always exhibit parallel with the mtDNA copy number, TFAM should be used judiciously as a marker of mitochondrial biogenesis  $[51]$  $[51]$ . There is evidence that the transcription level of *TFAM* increased along with the up-regulation of mtDNA during the diferentiation process of myoblasts [\[52](#page-17-20)], suggesting that *TFAM* is a suitable marker for mitochondrial biogenesis during myoblast differentiation. Therefore, the expression of *PGC1α*, *NRF1*, *TFAM* and mitochondrial-related gene (*ND1*, *CYTB*, *COX1*, *ATP6*) as well as mtDNA copy number were selected as the main indicators for measuring mitochondrial biogenesis. *NRF1* and *TFAM* expression are reduced in the skeletal muscle of GHRKO mice [\[53](#page-17-21)]. The expression of mitochondrial biogenesis markers (*PGC1α*, *NRF1*, *TFAM*) and mtDNA encoded OXPHOS gene are all down-regulated in SLD chicken skeletal muscle [\[54](#page-17-22)]. These results are consistent with our study, indicating that *GHR* plays a positive role in regulating mitochondrial biogenesis. We also revealed that *IGF1* promoted mitochondrial biogenesis during myoblast diferentiation, coinciding with the prior results that have been well summarized in our previous review [\[32](#page-17-2)]. Additionally, improving mitochondrial biogenesis is generally regarded as an ideal method to enhance cell function, which even can be used as a potential mitochondrial therapy [\[55](#page-17-23)]. Thus, we suggest that the GH-GHR-IGF1 axis may be used as a potential molecular target to promote mitochondrial biogenesis in the future.

The great complexity of the *GHR* on mitochondrial function is mirrored by the divergent results from a wide range of models*. GHR* knockout is harmful to the mitochondrial function of bone cells and fbroblasts [\[56](#page-17-24)]. Mitochondrial function is impaired in SLD chicken skeletal muscle [\[54](#page-17-22)]. We also revealed that *GHR* enhanced mitochondrial function during myoblast diferentiation. On the contrary, mitochondrial function of elderly GHRKO mice is enhanced in the liver, muscle, heart, kidney, and brain; three TCA cycle enzymes abundance (isocitrate dehydrogenase, fumarase and malate dehydrogenase) in the proteome of GHRKO pig liver is signifcantly increased, indicating that *GHR* inhibits mitochondrial function in vivo [[57,](#page-17-25) [58](#page-17-26)]. On the other hand, the efects of *IGF1* on mitochondrial biogenesis and mitochondrial function exhibited the consistent results, indicating that *IGF1* enhances mitochondrial function by regulating mitochondrial biogenesis in vitro. Counterintuitively, the ROS production did not increase with the reduction in  $\Delta \Psi$ m, but showed consistency with the trend of  $\Delta \Psi$ m in our present results. This may be explained by that mitochondrial proton leakage (due to the reduced  $\Delta \Psi$ m) can offset the ROS production under various physiological and pathological conditions to protect cells from oxidative stress, resulting in a positive correlation between ΔΨm and ROS production [\[59,](#page-17-27) [60](#page-17-28)]. Similarly, there is evidence that muscle mitochondrial dysfunction can be fred by a range of factors, but not all of them are decided by ROS production  $[61]$  $[61]$ .

Mitochondria provide ATP for the diferentiation process of myoblasts, and mitochondrial dysfunction impairs the myoblast diferentiation. Accordingly, mitochondrial biogenesis controls the energy supply requirements of myotubes [[62\]](#page-17-30). In C2C12, reduced *PGC1α* expression increases ROS production, mitochondrial damage, mitophagy, and ultimately inhibits the myoblast diferentiation [\[26](#page-16-21)]. Consistent with the results of Sotiropoulos et al. (2006), *GHR* knockdown repressed the diferentiation process of myoblast. According to the results above, we perceive that *GHR* knockdown inhibits mitochondrial biogenesis and further impairs mitochondrial function, resulting in insufficient ATP supply and ultimately repressing myoblast differentiation. This may also be the reason of the decrease in the number and diameter of muscle fbers in the SLD chicken skeletal muscle. Interestingly, previous studies have found that overexpression of *GHR* inhibits the formation of myotubes and the expression of myoblast diferentiation markers [[10\]](#page-16-9). We also revealed that overexpression of *GHR* inhibited myoblast diferentiation, which contradicts with the result of *GHR* overexpression promoted mitochondrial function during myoblast differentiation. This may be because the mRNA expression has reached at an exceeded level compared to the normal physiological conditions after *GHR* overexpression. Excessive accumulation of *GHR* mRNA may activate a certain feedback regulation mechanism to inhibit the myoblast diferentiation. Or excessive ROS production, induced by enhanced mitochondrial function after *GHR* overexpression, may inhibit the process of myoblast diferentiation.

IGF1 combines with IGF1R to activate a variety of downstream pathways to regulate cell activity. Thus, we try to explore the signal transduction involved in the regulation of mitochondrial biogenesis by *IGF1*; thereby unveil the mechanism by which *GHR* regulates mitochondrial biogenesis through *IGF1*. AKT overexpression enhances myoblast diferentiation [[63](#page-17-31)]. Phosphorylated AKT is decreased in the whole tissue homogenate of GHRKO mice, while is increased in bovine GH transgenic mice  $[64]$  $[64]$ . The protein levels of p-PI3K and p-AKT are decreased after knocking down *GHR* in gastric cancer cell lines [[65](#page-17-33)]. This is consistent with the result that *GHR* promotes the protein level of p-AKT during myoblast diferentiation. CREB is a transcription factor that induces the transcription of more than 100 genes under the control of cAMP response elements, including *PGC1α* [\[40](#page-17-10)]. Several studies have shown that AKT can activate CREB activity and

control cells survival [\[39](#page-17-9), [66](#page-17-34)[–68\]](#page-17-35). Knockdown of *IGF1* in chicken cardiomyocytes and myoblasts reduce the protein level of p-AKT [\[69](#page-17-36), [70\]](#page-17-37). Inhibition of the PI3K signaling pathway reduces the quality of mitochondria and the expression of OXPHOS-related genes, while inhibition of the MAPK signaling pathway has no efect on the quality of mitochondria [[22,](#page-16-22) [71](#page-17-38)]. Similarly, we revealed that *IGF1* promoted the protein level of p-AKT and p-CREB during myoblast diferentiation; inhibitors of PI3K/AKT signaling pathway signifcantly down-regulated the expression of *PGC1α* and its protein level. These compelling evidences demonstrate that *IGF1* regulates mitochondrial biogenesis through the PI3K/AKT signaling pathway.

In conclusion, we corroborate that local *GHR* acts as a control valve to enhance mitochondrial function by promoting mitochondrial biogenesis via IGF1-PI3K/AKT/ CREB pathway during myoblast diferentiation.

#### **Abbreviations**



#### **Supplementary Information**

The online version contains supplementary material available at [https://doi.](https://doi.org/10.1186/s12964-023-01166-5) [org/10.1186/s12964-023-01166-5](https://doi.org/10.1186/s12964-023-01166-5).

<span id="page-15-0"></span>**Additional fle 1: Table S1.** The sequences of primers for qRT-PCR. **Table S2.** The sequences of siRNA for *GHR* and *IGF1.*

<span id="page-15-1"></span>**Additional fle 2: Fig. S1** High *GHR* expression during myoblast differentiation. a The *GHR* expression profle in the CPM proliferation and diferentiation phases. b Transfection of overexpression plasmid or siRNA during CPM differentiation. c Overexpression efficiency of plasmid was measured by EGFP fuorescence intensity at 48 h after transfection with pcDNA3.1-EGFP during the CPM diferentiation; scaler bar, 200 μm. d Knockdown efficiency of siRNA was measured by Cy3 fluorescence

intensity at 48 h after transfection with siNC-Cy3 during the CPM differentiation; scaler bar, 200 μm. Data are shown as mean ± SEM, \*\**p* < 0.01. **Fig. S2** *GHR* overexpression promotes mitochondrial biogenesis. a Overexpression efficiency was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. b The expression of genes involved in the GH-GHR-IGFs signaling pathway was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. c and d MTG staining of CPM was measured at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. White arrow labeled elongated myoblasts. Scaler bar, 25 μm. e and f Confocal images were observed at 48 h after co-transfection with p*MitoTimer* + pcDNA3.1-*GHR* and p*MitoTimer* + pcDNA3.1-*GHR*. Scaler bar, 10 μm. Green represents newly synthesized mitochondria, red represents mature mitochondria. Images were analyzed by Leica LAS X life science software. g The expression of genes involved in PGC1α-NRF1-TFAM signaling pathway was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. h The expression of mtDNA encoded genes was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. i The relative mtDNA content was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. j-l Western blots with anti-GHR, anti-PGC1α, anti-NRF1 and anti-β-actin at48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. Data are shownas mean ± SEM, *\*p* < 0.05, \**\*p*< 0.01. **Fig. S3** *IGF1* overexpression promotes mitochondrial biogenesis. a Overexpression efficiency was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*IGF1*and pcDNA3.1. b The expression of genes involved in the GH-GHR-IGFs signaling pathway was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. c and d MTG staining of CPM was measured at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. White arrow labeled elongated myoblasts. Scaler bar, 25 μm. e and f Confocal images were observed at 48 h after co-transfection with p*MitoTimer* + pcDNA3.1-*IGF1* and p*MitoTimer* + pcDNA3.1-*IGF1*. Scaler bar, 10 μm. Green represents newly synthesized mitochondria, red represents mature mitochondria. Images were analyzed by Leica LAS X life science software. g The expression of genes involved in PGC1α-NRF1-TFAM signaling pathway was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. h The expression of mtDNA encoded genes was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. i The relative mtDNA content was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. j and k Western blots with anti-PGC1α, anti-NRF1 and anti-β-actin at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. Data are shown as mean  $\pm$  SEM,  $*p < 0.05$ ,  $**p < 0.01$ . Fig. **S4** Local *GHR* regulates mitochondrial biogenesis via IGF1-PI3K/AKT/CREB signaling. a and b Western blots with anti-JAK2, anti-p-JAK2, anti-AKT1, anti-p-AKT1, anti-CREB1, anti-p-CREB1 andanti-β-actin at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. c and d Western blots with anti-AKT1, anti-p-AKT1, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. e The expression of *CREB* and *PGC1α* was measured by RT-qPCR at 48 h after transfection with si-*CREB* and si-NC. f and g Western blots with anti-PGC1α, anti-CREB1, anti-p-CREB1 and anti-β-actin at 48 h after transfection with si-*CREB* and si-NC. h Dual-Luciferase report assays of *CREB* knockdown co-transfected with reporter vectors containing diferent length of 5′ upstream region of *PGC1α*. Data are shown as mean ± SEM, \**p* < 0.05, \*\**p* < 0.01. **Fig. S5** *GHR* or *IGF1* overexpression enhances mitochondrial function. a ΔΨm was measured by the fuorescence of JC-1 at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. b ΔΨm was measured by the fuorescence of JC-1 at 48 h after transfectionwith pcDNA3.1-*IGF1* and pcDNA3.1. c ATP level was measured at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. d Reactive oxygen species production was measured by the fuorescence of DCF at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. e ATP level was measured at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. f Reactive oxygen species production was measured by the fuorescence of DCF at 48 h after transfection with pcDNA3.1-*IGF1* and pcDNA3.1. Data are shown as mean ± SEM, \**p* < 0.05, \*\**p*< 0.01. **Fig. S6** *GHR* overexpression represses myoblast diferentiation. a CCK-8 assays were performed after transfection with pcDNA3.1-*GHR* and pcDNA3.1. b and c EdU proliferation assays were performed after transfection with pcDNA3.1-*GHR* and pcDNA3.1. d Cell cycle analysis were

performed after transfection with pcDNA3.1-*GHR* and pcDNA3.1. e The expression of cell proliferation marker genes was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. f-h MyHC staining, myotube area and myoblast fusion index were measured at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. i The expression of myoblast diferentiation marker genes was measured by RT-qPCR at 48 h after transfection with pcDNA3.1-*GHR* and pcDNA3.1. Data are shown as mean ± SEM, \**p* < 0.05, \*\**p* < 0.01.

#### **Acknowledgements**

We would like to thank Prof. Henna Tyynismaa from Faculty of Medicine, University of Helsinki, Helsinki, Finland for her comments and suggestions on the manuscript.

#### **Authors' contributions**

B.H. designed the study, wrote the manuscript, carried out the experiments and analyzed the data. C.Z. and H.W. conducted some experiments and analyzed the data. X.P., G.M., M.X. participated in data collection and interpretation. H.L., Q.N. and W.L. engaged in study interpretation. X.Z. developed the concepts, designed, and supervised the study. All authors contributed to the article and approved the submitted version.

#### **Funding**

This work was supported by grants from the China Agriculture Research System of MOF and MARA (CARS-41), National Key R&D Program of China (2021YFD1300100), and China Scholarship Council (202108440354).

#### **Availability of data and materials**

All data generated or analyzed during this study are available from the corresponding author on reasonable request.

#### **Declarations**

#### **Ethics approval and consent to participate**

All animal experiments were performed according to the protocols approved by the South China Agriculture University Institutional Animal Care and Use Committee. All animal procedures followed the regulations and guidelines established by this committee and minimized the sufering of animals.

#### **Consent for publication**

Not applicable.

#### **Competing interests**

The authors declare that they have no competing interests.

#### **Author details**

<sup>1</sup> State Key Laboratory of Livestock and Poultry Breeding, South China Agricultural University, Guangzhou, Guangdong, China. <sup>2</sup>State Key Laboratory for Conservation and Utilization of Subtropical Agro-Bioresources and Lingnan Guangdong Laboratory of Agriculture, South China Agricultural University, Guangzhou, Guangdong, China. <sup>3</sup> Department of Animal Genetics, Breeding and Reproduction, College of Animal Science, South China Agricultural University, Guangzhou, Guangdong, China.

## Received: 6 March 2023 Accepted: 13 May 2023

#### **References**

- <span id="page-16-0"></span>de Vos AM, Ultsch M, Kossiakoff AA. Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science. 1992;255:306–12.
- <span id="page-16-1"></span>2. Kopchick JJ, Andry JM. Growth hormone (GH), GH receptor, and signal transduction. Mol Genet Metab. 2000;71:293–314.
- <span id="page-16-2"></span>Brooks AJ, Wooh JW, Tunny KA, Waters MJ. Growth hormone receptor; mechanism of action. Int J Biochem Cell B. 2008;40:1984–9.
- <span id="page-16-3"></span>4. Vanderkuur JA, Butch ER, Waters SB, Pessin JE, Guan KL, Carter-Su C. Signaling molecules involved in coupling growth hormone receptor

to mitogen-activated protein kinase activation. Endocrinology. 1997;138:4301–7.

- <span id="page-16-4"></span>5. Hayashi AA, Proud CG. The rapid activation of protein synthesis by growth hormone requires signaling through mTOR. Am J Physiol-Endoc M. 2007;292:E1647–55.
- <span id="page-16-5"></span>6. Bergan HE, Kittilson JD, Sheridan MA. Nutritional state modulates growth hormone-stimulated lipolysis. Gen Comp Endocr. 2015;217–218:1–9.
- <span id="page-16-6"></span>7. Ranke MB, Wit JM. Growth hormone - past, present and future. Nat Rev Endocrinol. 2018;14:285–300.
- <span id="page-16-7"></span>8. Wosczyna MN, Rando TA. A muscle stem cell support group: coordinated cellular responses in muscle regeneration. Dev Cell. 2018;46:135–43.
- <span id="page-16-8"></span>9. Chal J, Pourquie O. Making muscle: skeletal myogenesis in vivo and in vitro. Development. 2017;144:2104–22.
- <span id="page-16-9"></span>10. Segard HB, Moulin S, Boumard S, Augier DCC, Kelly PA, Finidori J. Autocrine growth hormone production prevents apoptosis and inhibits diferentiation in C2C12 myoblasts. Cell Signal. 2003;15:615–23.
- <span id="page-16-10"></span>11. Burke WH, Moore JA, Ogez JR, Builder SE. The properties of recombinant chicken growth hormone and its efects on growth, body composition, feed efficiency, and other factors in broiler chickens. Endocrinology. 1987;120:651–8.
- <span id="page-16-11"></span>12. Rosebrough RW, McMurtry JP, Vasilatos-Younken R. Efect of pulsatile or continuous administration of pituitary-derived chicken growth hormone (p-cGH) on lipid metabolism in broiler pullets. Comp Biochem Physiol A Comp Physiol. 1991;99:207–14.
- <span id="page-16-12"></span>13. Halevy O, Hodik V, Mett A. The effects of growth hormone on avian skeletal muscle satellite cell proliferation and diferentiation. Gen Comp Endocr. 1996;101:43–52.
- <span id="page-16-13"></span>14. Mavalli MD, DiGirolamo DJ, Fan Y, Riddle RC, Campbell KS, van Groen T, et al. Distinct growth hormone receptor signaling modes regulate skeletal muscle development and insulin sensitivity in mice. J Clin Invest. 2010;120:4007–20.
- <span id="page-16-14"></span>15. Sotiropoulos A, Ohanna M, Kedzia C, Menon RK, Kopchick JJ, Kelly PA, et al. Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. P Natl Acad Sci Usa. 2006;103:7315–20.
- <span id="page-16-15"></span>16. Luo W, Lin S, Li G, Nie Q, Zhang X. Integrative analyses of miRNA-mRNA Interactions reveal let-7b, miR-128 and MAPK pathway involvement in muscle mass loss in sex-linked dwarf chickens. Int J Mol Sci. 2016;17:276.
- <span id="page-16-16"></span>17. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.
- <span id="page-16-17"></span>18. Duguez S, Sabido O, Freyssenet D. Mitochondrial-dependent regulation of myoblast proliferation. Exp Cell Res. 2004;299:27–35.
- <span id="page-16-18"></span>19. Herzberg NH, Zwart R, Wolterman RA, Ruiter JP, Wanders RJ, Bolhuis PA, et al. Diferentiation and proliferation of respiration-defcient human myoblasts. Biochim Biophys Acta. 1993;1181:63–7.
- 20. Herzberg NH, Middelkoop E, Adorf M, Dekker HL, Van Galen MJ, Van den Berg M, et al. Mitochondria in cultured human muscle cells depleted of mitochondrial DNA. Eur J Cell Biol. 1993;61:400–8.
- 21. Seyer P, Grandemange S, Busson M, Carazo A, Gamaleri F, Pessemesse L, et al. Mitochondrial activity regulates myoblast diferentiation by control of c-Myc expression. J Cell Physiol. 2006;207:75–86.
- <span id="page-16-22"></span>22. Pawlikowska P, Gajkowska B, Hocquette JF, Orzechowski A. Not only insulin stimulates mitochondriogenesis in muscle cells, but mitochondria are also essential for insulin-mediated myogenesis. Cell Proliferat. 2006;39:127–45.
- 23. Rochard P, Rodier A, Casas F, Cassar-Malek I, Marchal-Victorion S, Daury L, et al. Mitochondrial activity is involved in the regulation of myoblast diferentiation through myogenin expression and activity of myogenic factors. J Biol Chem. 2000;275:2733–44.
- <span id="page-16-19"></span>24. Hamai N, Nakamura M, Asano A. Inhibition of mitochondrial protein synthesis impaired C2C12 myoblast diferentiation. Cell Struct Funct. 1997;22:421–31.
- <span id="page-16-20"></span>25. Kraft CS, LeMoine CM, Lyons CN, Michaud D, Mueller CR, Moyes CD. Control of mitochondrial biogenesis during myogenesis. Am J Physiol-Cell Ph. 2006;290:C1119–27.
- <span id="page-16-21"></span>26. Sin J, Andres AM, Taylor DJ, Weston T, Hiraumi Y, Stotland A, et al. Mitophagy is required for mitochondrial biogenesis and myogenic diferentiation of C2C12 myoblasts. Autophagy. 2016;12:369–80.
- 27. Baechler BL, Bloemberg D, Quadrilatero J. Mitophagy regulates mitochondrial network signaling, oxidative stress, and apoptosis during myoblast diferentiation. Autophagy. 2019;15:1606–19.
- 28. Lampert MA, Orogo AM, Najor RH, Hammerling BC, Leon LJ, Wang BJ, et al. BNIP3L/NIX and FUNDC1-mediated mitophagy is required for mitochondrial network remodeling during cardiac progenitor cell differentiation. Autophagy. 2019;15:1182–98.
- 29. Remels AH, Langen RC, Schrauwen P, Schaart G, Schols AM, Gosker HR. Regulation of mitochondrial biogenesis during myogenesis. Mol Cell Endocrinol. 2010;315:113–20.
- <span id="page-17-0"></span>30. Rahman FA, Quadrilatero J. Mitochondrial network remodeling: an important feature of myogenesis and skeletal muscle regeneration. Cell Mol Life Sci. 2021;78:4653–75.
- <span id="page-17-1"></span>31. Attardi G, Schatz G. Biogenesis of Mitochondria. Annu Rev Cell Biol. 1988;4:289–333.
- <span id="page-17-2"></span>32. Hu B, Li H, Zhang X. A balanced act: the efects of GH-GHR-IGF1 axis on mitochondrial function. Front Cell Dev Biol. 2021;9: 630248.
- <span id="page-17-3"></span>33. Luo W, Wu H, Ye Y, Li Z, Hao S, Kong L, et al. The transient expression of miR-203 and its inhibiting efects on skeletal muscle cell proliferation and diferentiation. Cell Death Dis. 2014;5: e1347.
- <span id="page-17-4"></span>34. Zhang L, Lin S, An L, Ma J, Qiu F, Jia R, et al. Chicken GHR natural antisense transcript regulates GHR mRNA in LMH cells. Oncotarget. 2016;7:73607–17.
- <span id="page-17-5"></span>35. Laker RC, Xu P, Ryall KA, Sujkowski A, Kenwood BM, Chain KH, et al. A novel MitoTimer reporter gene for mitochondrial content, structure, stress, and damage in vivo. J Biol Chem. 2014;289:12005–15.
- <span id="page-17-6"></span>36. Sjogren K, Liu JL, Blad K, Skrtic S, Vidal O, Wallenius V, et al. Liver-derived insulin-like growth factor I (IGF-I) is the principal source of IGF-I in blood but is not required for postnatal body growth in mice. P Natl Acad Sci Usa. 1999;96:7088–92.
- <span id="page-17-7"></span>37. Junnila RK, List EO, Berryman DE, Murrey JW, Kopchick JJ. The GH/IGF-1 axis in ageing and longevity. Nat Rev Endocrinol. 2013;9:366–76.
- <span id="page-17-8"></span>38. Giorgetti S, Ballotti R, Kowalski-Chauvel A, Tartare S, Van Obberghen E. The insulin and insulin-like growth factor-I receptor substrate IRS-1 associates with and activates phosphatidylinositol 3-kinase in vitro. J Biol Chem. 1993;268:7358–64.
- <span id="page-17-9"></span>39. Du K, Montminy M. CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem. 1998;273:32377–9.
- <span id="page-17-10"></span>40. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature. 2001;413:179–83.
- <span id="page-17-11"></span>41. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev. 1995;16:3–34.
- <span id="page-17-12"></span>42. Liu Y, Guo W, Pu Z, Li X, Lei X, Yao J, et al. Developmental changes of Insulin-like growth factors in the liver and muscle of chick embryos. Poultry Sci. 2016;95:1396–402.
- <span id="page-17-13"></span>43. Allan GJ, Zannoni A, McKinnell I, Otto WR, Holzenberger M, Flint DJ, et al. Major components of the insulin-like growth factor axis are expressed early in chicken embryogenesis, with IGF binding protein ( IGFBP) -5 expression subject to regulation by Sonic Hedgehog. Anat Embryol (Berl). 2003;207:73–84.
- <span id="page-17-14"></span>44. Yakar S, Liu JL, Stannard B, Butler A, Accili D, Sauer B, et al. Normal growth and development in the absence of hepatic insulin-like growth factor I. P Natl Acad Sci Usa. 1999;96:7324–9.
- <span id="page-17-15"></span>45. Gleyzer N, Vercauteren K, Scarpulla RC. Control of mitochondrial transcription specifcity factors (TFB1M and TFB2M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol Cell Biol. 2005;25:1354–66.
- 46. Scarpulla RC. Transcriptional paradigms in mammalian mitochondrial biogenesis and function. Physiol Rev. 2008;88:611–38.
- 47. Scarpulla RC, Vega RB, Kelly DP. Transcriptional integration of mitochondrial biogenesis. Trends Endocrin Met. 2012;23:459–66.
- <span id="page-17-17"></span>48. Villena JA. New insights into PGC-1 coactivators: redefning their role in the regulation of mitochondrial function and beyond. Febs J. 2015;282:647–72.
- <span id="page-17-16"></span>49. Popov LD. Mitochondrial biogenesis: An update. J Cell Mol Med. 2020;24:4892–9.
- <span id="page-17-18"></span>50. Zhu J, Wang KZ, Chu CT. After the banquet: mitochondrial biogenesis, mitophagy, and cell survival. Autophagy. 2013;9:1663–76.
- <span id="page-17-19"></span>51. Kozhukhar N, Alexeyev MF. Limited predictive value of TFAM in mitochondrial biogenesis. Mitochondrion. 2019;49:156–65.
- <span id="page-17-20"></span>52. Collu-Marchese M, Shuen M, Pauly M, Saleem A, Hood DA. The regulation of mitochondrial transcription factor A (Tfam) expression during skeletal muscle cell diferentiation. Bioscience Rep. 2015;35(3):e00221.
- <span id="page-17-21"></span>53. Gesing A, Masternak MM, Wang F, Joseph AM, Leeuwenburgh C, Westbrook R, et al. Expression of key regulators of mitochondrial biogenesis in growth hormone receptor knockout (GHRKO) mice is enhanced but is not further improved by other potential life-extending interventions. J Gerontol a-Biol. 2011;66:1062–76.
- <span id="page-17-22"></span>54. Hu B, Hu S, Yang M, Liao Z, Zhang D, Luo Q, et al. Growth hormone receptor gene is essential for chicken mitochondrial function in vivo and in vitro. Int J Mol Sci. 2019;20(7):1608.
- <span id="page-17-23"></span>55. Viscomi C, Bottani E, Zeviani M. Emerging concepts in the therapy of mitochondrial disease. Biochim Biophys Acta. 2015;1847:544–57.
- <span id="page-17-24"></span>56. Liu Z, Solesio ME, Schaffler MB, Frikha-Benayed D, Rosen CJ, Werner H, et al. Mitochondrial function is compromised in cortical bone osteocytes of long-lived growth hormone receptor null mice. J Bone Miner Res. 2019;34:106–22.
- <span id="page-17-25"></span>57. Brown-Borg HM, Rakoczy SG, Sharma S, Bartke A. Long-living growth hormone receptor knockout mice: potential mechanisms of altered stress resistance. Exp Gerontol. 2009;44:10–9.
- <span id="page-17-26"></span>58. Riedel EO, Hinrichs A, Kemter E, Dahlhoff M, Backman M, Rathkolb B, et al. Functional changes of the liver in the absence of growth hormone (GH) action - proteomic and metabolomic insights from a GH receptor defcient pig model. Mol Metab. 2020;36: 100978.
- <span id="page-17-27"></span>59. Turrens JF. Mitochondrial formation of reactive oxygen species. J Physiol-London. 2003;552:335–44.
- <span id="page-17-28"></span>60. Mailloux RJ, Harper ME. Uncoupling proteins and the control of mitochondrial reactive oxygen species production. Free Radical Bio Med. 2011;51:1106–15.
- <span id="page-17-29"></span>61. Mogensen M, Sahlin K, Fernstrom M, Glintborg D, Vind BF, Beck-Nielsen H, et al. Mitochondrial respiration is decreased in skeletal muscle of patients with type 2 diabetes. Diabetes. 2007;56:1592–9.
- <span id="page-17-30"></span>62. Nichenko AS, Southern WM, Atuan M, Luan J, Peissig KB, Foltz SJ, et al. Mitochondrial maintenance via autophagy contributes to functional skeletal muscle regeneration and remodeling. Am J Physiol-Cell Ph. 2016;311:C190-200.
- <span id="page-17-31"></span>63. Tureckova J, Wilson EM, Cappalonga JL, Rotwein P. Insulin-like growth factor-mediated muscle diferentiation: collaboration between phosphatidylinositol 3-kinase-Akt-signaling pathways and myogenin. J Biol Chem. 2001;276:39264–70.
- <span id="page-17-32"></span>64. Al-Regaiey KA, Masternak MM, Bonkowski M, Sun L, Bartke A. Longlived growth hormone receptor knockout mice: interaction of reduced insulin-like growth factor i/insulin signaling and caloric restriction. Endocrinology. 2005;146:851–60.
- <span id="page-17-33"></span>65. Yan HZ, Wang HF, Yin Y, Zou J, Xiao F, Yi LN, et al. GHR is involved in gastric cell growth and apoptosis via PI3K/AKT signalling. J Cell Mol Med. 2021;25:2450–8.
- <span id="page-17-34"></span>66. Jain V, Baitharu I, Prasad D, Ilavazhagan G. Enriched environment prevents hypobaric hypoxia induced memory impairment and neurodegeneration: role of BDNF/PI3K/GSK3beta pathway coupled with CREB activation. PLoS ONE. 2013;8: e62235.
- 67. Simao F, Matte A, Pagnussat AS, Netto CA, Salbego CG. Resveratrol prevents CA1 neurons against ischemic injury by parallel modulation of both GSK-3beta and CREB through PI3-K/Akt pathways. Eur J Neurosci. 2012;36:2899–905.
- <span id="page-17-35"></span>68. Stewart R, Flechner L, Montminy M, Berdeaux R. CREB is activated by muscle injury and promotes muscle regeneration. PLoS ONE. 2011;6: e24714.
- <span id="page-17-36"></span>69. Gong Y, Yang J, Liu Q, Cai J, Zheng Y, Zhang Y, et al. IGF1 Knockdown hinders myocardial development through energy metabolism dysfunction caused by ROS-dependent FOXO activation in the chicken heart. Oxid Med Cell Longev. 2019;2019:7838754.
- <span id="page-17-37"></span>70. Saneyasu T, Nakamura T, Honda K, Kamisoyama H. IGF-1 knockdown inhibits phosphorylation of Akt and ERK in chicken embryonic myotubes. Growth Horm Igf Res. 2022;65: 101478.
- <span id="page-17-38"></span>71. Lyons A, Coleman M, Riis S, Favre C, O'Flanagan CH, Zhdanov AV, et al. Insulin-like growth factor 1 signaling is essential for mitochondrial biogenesis and mitophagy in cancer cells. J Biol Chem. 2017;292:16983–98.

#### **Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.